Myositis-specific autoantibodies (MSAs) have become pivotal biomarkers for idiopathic inflammatory myopathies and have revolutionized understanding of the heterogeneous disease spectrum that affects both adults and children. The discovery and characterization of MSAs have substantially enhanced patient stratification based on clinical phenotype, thereby facilitating more precise diagnosis and ultimately improving management strategies. Advances in immunoassay technologies in the past 20 years have further propelled the field forward, enabling the detection of a growing repertoire of autoantibodies with high specificity and sensitivity; however, evolving research over the past decade has revealed that even within antibody-defined subsets, considerable clinical diversity exists, suggesting a broader spectrum of disease manifestations than previously acknowledged. Challenges persist, particularly among patients who are seronegative, where the failure to identify certain rare MSAs stems from the use of diverse detection methodologies and inadequate consensus-guided standardization and validation protocols. Bridging these diagnostic gaps is crucial for optimizing patient care and refining prognostic stratification in idiopathic inflammatory myopathies.

Nur Azizah Allameen

Ana Isabel Ramos-Lisbona

Lucy R. Wedderburn

Ingrid E. Lundberg

David A. Isenberg

Nature Reviews Rheumatology

期刊范围涵盖风湿病研究的整个范围。我们确保我们的文章可供最广泛的受众访问。

Nature Reviews Rheumatology covers the entire spectrum of rheumatology research. We are committed to ensuring that our articles are accessible to the widest possible audience.

《Nature Reviews Rheumatology》期刊涵盖了风湿病研究的各个领域。我们致力于确保我们的文章能够被最广泛的受众所访问。

Category	Quartile
医学	1
医学, 风湿病学	1

An update on autoantibodies in the idiopathic inflammatory myopathies

ivySCI AI Smartly Parses PDF, Answers Researchers' Questions, and Helps You Understand Papers in Seconds

Journal Info